Gamida Cell - Cell and Immune Therapy Technologies

Latest News

View All

Nov 23, 2022

Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences

Gamida Cell Provides Regulatory Update on Omidubicel

Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update

Gamida Cell to Present Corporate Highlights at the Jefferies London Healthcare Conference

GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers

Gamida Cell Announces the Date of Its Third Quarter 2022 Financial Results and Webcast

Gamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual Meeting

Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa

Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting

Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares

Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing

Gamida Cell Announces Launch of Public Offering of Ordinary Shares

Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies

Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting

Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update

Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast

Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review

Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference

Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors

Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel

Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference

Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference

Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update

Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022

Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast

Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201

Gamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health Equity and Health Outcomes With Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Gamida Cell to Present Corporate Highlights and Participate in Panel Discussion at the Needham Healthcare Conference

Gamida Cell Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

Gamida Cell to Present Corporate Highlights at the Oppenheimer 32nd Annual Healthcare Conference

Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results and Webcast

Gamida Cell Initiates Rolling Submission of Biologics License Application for Omidubicel

Gamida Cell Announces Appointment of Anat Cohen-Dayag and Naama Halevi-Davidov to its Board of Directors

Gamida Cell Provides Key Program Updates and 2022 Financial Guidance

Gamida Cell Provides Update on Omidubicel BLA Submission

Gamida Cell Announces Data to be Presented at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Gamida Cell Presents Two-Year Survival Data for GDA-201 and Resource Utilization Analysis for Omidubicel at 63rd ASH Annual Meeting

Gamida Cell Presents New Omidubicel Data at 63rd ASH Annual Meeting

Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences

Gamida Cell Reports Third Quarter 2021 Financial Results and Provides Company Update

Gamida Cell Provides Update on Pre-BLA Meeting With FDA for Omidubicel

Gamida Cell Presents New Data on Nicotinamide-Enabled NK Cell Therapy at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

Gamida Cell Announces the Date of Its Third Quarter 2021 Financial Results and Webcast

Gamida Cell Announces Data to Be Presented at 63rd ASH Annual Meeting

Gamida Cell Presents Data on its NAM-Enabled NK Cell Therapies at Protein & Antibody Engineering Summit (PEGS) Europe

Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today’s Virtual R&D Day

Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

Gamida Cell to Host Virtual Event Highlighting GDA-201 and NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline

Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in September

Gamida Cell Reports Second Quarter 2021 Financial Results and Provides Company Update

Gamida Cell Announces the Date of Its Second Quarter 2021 Financial Results and Webcast

Gamida Cell to Present at the BTIG Virtual Biotechnology Conference

Gamida Cell Announces Publication in Blood, the Journal of the American Society of Hematology, of the First Pivotal Trial to Evaluate a Cell Therapy (Omidubicel) for Patients with Blood Cancer who Require an Allogeneic Stem Cell Transplant

Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in June

Gamida Cell Announces Appointment of Senior Vice President, Global Operations and Manufacturing and Provides Commercial Manufacturing Update

Gamida Cell to Present at the RBC Capital Markets Global Healthcare Conference

Gamida Cell Reports First Quarter 2021 Financial Results and Provides Company Update

Gamida Cell Announces the Date of Its First Quarter 2021 Financial Results and Webcast

Gamida Cell to Present at the 20th Annual Needham Virtual Healthcare Conference

Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

Gamida Cell Reports Full Year 2020 Financial Results and Provides Company Update

Gamida Cell to Present at Upcoming Investor Conferences

Gamida Cell Announces the Date of Its Full Year 2020 Financial Results and Webcast

Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

Gamida Cell Announces $75 Million Financing with Highbridge Capital Management

Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 2021 TCT Meetings of ASTCT and CIBMTR

Gamida Cell to Present Full Data from Phase 3 Study of Omidubicel at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR

Gamida Cell to Present at Upcoming January Investor Conferences

Gamida Cell Announces Closing of $75 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Gamida Cell Added to NASDAQ Biotechnology Index

Gamida Cell Announces Pricing of $65 Million Public Offering of Ordinary Shares

Gamida Cell Announces Launch of Public Offering of Ordinary Shares

Gamida Cell Provides Regulatory Update on Biologics License Application for Omidubicel

Gamida Cell Provides Pipeline Update, Including Detailed Results of Pivotal Phase 3 Clinical Study of Omidubicel, and Prepares to Start BLA Submission by End of 2020

Gamida Cell Presents Updated, Expanded Results from Phase 1 Study of Natural Killer Cell Therapy GDA-201 at ASH Annual Meeting and Exposition

Gamida Cell to Host Virtual Pipeline Deep Dive

Gamida Cell to Present at Upcoming Conferences

Gamida Cell Reports Third Quarter 2020 Financial Results and Provides Company Update

Gamida Cell Announces Data to Be Presented at 62nd ASH Annual Virtual Meeting

Gamida Cell to Present at H.C. Wainwright 6th Annual Israel Conference

Gamida Cell Announces the Date of Its Third Quarter 2020 Financial Results and Webcast

Gamida Cell and Be The Match BioTherapies® Expand Strategic Collaboration

Gamida Cell to Present at 2020 Virtual Cell & Gene Meeting on the Mesa

Gamida Cell Announces Positive Topline Data on Secondary Endpoints from Phase 3 Clinical Study of Omidubicel in Patients with Hematologic Malignancies

Gamida Cell Presents Analysis of Observational Data Demonstrating the Impact of Donor Age in Hematopoietic Stem Cell Transplant Outcomes at the Virtual Cord Blood Connect Meeting

Gamida Cell to Participate in Upcoming Investor Conferences

Gamida Cell Announces Two-Part Virtual Miniseries Focused on Omidubicel to Take Place in September

Gamida Cell to Provide Webcast of Its Annual Meeting of Stockholders

Gamida Cell Reports Second Quarter 2020 Financial Results and Provides Company Update

Gamida Cell Announces the Date of Its Second Quarter 2020 Financial Results and Webcast

Gamida Cell Announces Appointment of Michele Korfin as Chief Operating and Chief Commercial Officer

Gamida Cell Announces Appointment of David Fox to Its Board of Directors

Gamida Cell to Present at the JMP Securities Virtual Hematology and Oncology Forum

Gamida Cell Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

Gamida Cell Reports First Quarter 2020 Financial Results and Provides Company Update

Gamida Cell Announces Pricing of $60 Million Public Offering of Ordinary Shares

Patient focus

The needs and experiences of patients are at the core of our mission and purpose. Read about one woman’s personal journey through cancer diagnosis, treatment and more than 10 years as a survivor.

Meet Stacey

Future of cancer care

We are creating a pipeline of NAM-enabled cell therapies designed to deliver a curative approach for patients with cancer.

Learn more

Dedicated team

We combine bold and creative pursuits in science with a passion for curing cancer so that patients can live longer, better lives.

Meet us

Committed to Cures

Pioneering next-generation cell therapies for patients with cancer and other serious diseases

Latest News

Nov 23, 2022

Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences

Nov 21, 2022

Gamida Cell Provides Regulatory Update on Omidubicel

Nov 14, 2022

Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update

Nov 10, 2022

Gamida Cell to Present Corporate Highlights at the Jefferies London Healthcare Conference

Nov 07, 2022

GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers

Nov 07, 2022

Gamida Cell Announces the Date of Its Third Quarter 2022 Financial Results and Webcast

Nov 03, 2022

Gamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual Meeting

Oct 10, 2022

Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa

Sep 29, 2022

Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting

Sep 28, 2022

Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares

Sep 28, 2022

Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing

Sep 27, 2022

Gamida Cell Announces Launch of Public Offering of Ordinary Shares

Sep 19, 2022

Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies

Sep 12, 2022

Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting

Aug 15, 2022

Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update

Aug 10, 2022

Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

Aug 08, 2022

Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast

Aug 01, 2022

Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review

Jun 13, 2022

Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference

Jun 10, 2022

Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors

Jun 02, 2022

Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel

Jun 01, 2022

Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference

Jun 01, 2022

Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

May 17, 2022

Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference

May 10, 2022

Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update

May 05, 2022

Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022

May 03, 2022

Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast

Apr 27, 2022

Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Apr 26, 2022

Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201

Apr 25, 2022

Gamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Apr 25, 2022

Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health Equity and Health Outcomes With Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Apr 07, 2022

Gamida Cell to Present Corporate Highlights and Participate in Panel Discussion at the Needham Healthcare Conference

Mar 15, 2022

Gamida Cell Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

Mar 10, 2022

Gamida Cell to Present Corporate Highlights at the Oppenheimer 32nd Annual Healthcare Conference

Mar 08, 2022

Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results and Webcast

Feb 09, 2022

Gamida Cell Initiates Rolling Submission of Biologics License Application for Omidubicel

Jan 31, 2022

Gamida Cell Announces Appointment of Anat Cohen-Dayag and Naama Halevi-Davidov to its Board of Directors

Jan 31, 2022

Gamida Cell Provides Key Program Updates and 2022 Financial Guidance

Jan 19, 2022